Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

Core Viewpoint - Inspira Technologies OXY B.H.N. Ltd. has appointed Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025, aiming to enhance the company's leadership and strategic vision in the medical technology sector [1][4]. Company Leadership - Mr. Tal Parnes brings over three decades of experience in the technology sector, particularly in medical technology and pharmaceuticals, and has served as an independent director of the company since July 2021 [1][2]. - His previous roles include co-founding and serving as CEO of Zuta-Core Ltd. and HQL Pharmaceuticals Ltd., as well as holding executive positions at Silynx Communications Inc., Wavion Inc., Atrica Ltd., and Printlife Ltd. [3]. Strategic Impact - Mr. Parnes' leadership is expected to refine the company's strategic vision and bolster its competitive advantage in the market, positioning the company for sustainable success [4]. - The company expresses gratitude to Prof. Benad Goldwasser for his contributions as chairman since 2021, highlighting his support during the company's Nasdaq listing [5]. Product Innovation - Inspira Technologies is focused on life-support technology, having developed the Augmented Respiration Technology (INSPIRA™ ART), which aims to revolutionize the $19 billion mechanical ventilation market [6]. - The INSPIRA ART provides an alternative for patients with acute respiratory failure, stabilizing oxygen saturation levels without the need for a ventilator, allowing patients to remain awake during treatment [6]. Regulatory Approvals - The INSPIRA™ ART100 system has received FDA 510(k) clearance for use in cardiopulmonary bypass procedures and has also obtained Israeli AMAR certification for similar applications [7]. Future Developments - The company is in the process of designing and developing additional products, including the INSPIRA™ ART500, INSPIRA™ Cardi-ART, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, which are not yet tested or approved for human use [8].